

International Conference on Dementia and Brain Disorders  
&  
2<sup>nd</sup> International Conference on Neurology & Neurological Disorders  
November 15, 2024 | Virtual Event



## Hermann Kurt Russ

Galimedix Therapeutics  
USA

### Small molecules GAL-101 and GAL-201 as potential oral treatments for Alzheimer's disease

#### Abstract:

There is a growing body of evidence that toxic oligomers and protofibrils of amyloid beta ( $A\beta$ ) are an underlying cause of Alzheimer's disease. Recent approvals and promising Phase 3 results of anti- $A\beta$  antibody drugs have validated them as a key target for that disease. Galimedix Therapeutics is developing orally administered  $A\beta$  aggregation modulators that target the beginning of the  $A\beta$  peptide aggregation cascade. Our candidates GAL-101 and GAL-201 act upstream to most other  $A\beta$ -targeting approaches on the market and in advanced development, potentially enabling them to effectively impact disease progression without disturbing normal neuronal function. GAL-101 and GAL-201 prevent the formation of all toxic  $A\beta$  oligomers that drive neurodegeneration at the source by binding to a specific motif only exposed in the misfolded  $A\beta$  monomers, triggering the clustering of these misfolded  $A\beta$  monomers and preventing the assembly of harmful oligomers. Data from long-term-potential (LTP) and from animal studies will be presented supporting the mechanism of action and the beneficial biological effects on cognition. An oral Phase 1 study with the lead molecule GAL-101 has been initiated and will enroll the first subjects still this year. With this data, a clinical Phase 2 "Proof-of-concept" study in Alzheimer patients is planned for 2026. Galimedix is a privately owned biotech company.

#### Biography

**Russ** is a board-certified clinical neurologist and a professor of pharmacology. He holds a Ph.D. in neuro- and bio-chemistry from the University of Wurzburg, Germany. After his academic career, Dr. Russ joined the pharmaceutical industry and worked 25 years for several international companies including Merck, Teva, and Merz in leading positions in research and development. His scientific focus is on neuro-degenerative diseases, including Alzheimer's, Parkinson's, and degenerative retina diseases. He is (co)inventor of over 25 patents and (co) author of more than 50 peer-reviewed scientific publications. He is co-founder of Galimedix Therapeutics ([www.galimedix.com](http://www.galimedix.com)) and lives in Dubai